Silver Book Fact

Resolvins, a family of lipid mediators, have shown potential in resolving persistent inflammatory pain.

Xu Z, Zhang L, Liu T, Park J, et al. Resolvins RvE1 and RvD1 Attenuate Inflammatory Pain Via Central and Peripheral Actions. Nature Med. 2010; 16(5): 592-7. http://www.nature.com/nm/journal/v16/n5/full/nm.2123.html

Reference

Title
Resolvins RvE1 and RvD1 Attenuate Inflammatory Pain Via Central and Peripheral Actions
Publication
Nature Med
Publication Date
2010
Authors
Xu Z, Zhang L, Liu T, Park J, et al
Volume & Issue
Volume 16, Issue 5
Pages
592-7
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Understanding the role of genetics in pain mechanisms is increasing and the potential now exists to conduct genome-wide screens in model organisms to look for pain-associated genes.  
  • Pain education programs and pain consultations have been found to improve pain (average pain was 31% versus 20%) and daily interference (20% versus 2.5%) in oncology outpatients. Patient adherence…  
  • An opiate agonist often used for persistent pain, tramadol was found in one meta-analysis to significantly reduce neuropathic pain when compared to placebo.  
  • The use of sodium oxybate (SXB) in fibromylagia patients reduced pain by 30% or more in 54-58% of patients (versus 35.2% for placebo). SXB also reduced fatigue and sleep disturbance.  
  • Subthalamic nuclei deep brain stimulation (STN-DBS) raises pain thresholds in Parkinson’s disease patients.